Lilly announces promising results for Pirtobrutinib Phase 1/2 trials
Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More
BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia
BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with ... Read More
Ascentage Pharma gets FDA ODD for APG-2575 in Waldenström macroglobulinemia
Ascentage Pharma has been granted orphan drug designation (ODD) for its Bcl-2 inhibitor APG-2575 from the US Food and Drug Administration (FDA) for the treatment ... Read More